Georgia's Pathways to Coverage program struggles with low enrollment and retention due to bureaucratic complexities, impacting Medicaid work requirement policy effectiveness.

Explore Medicaid's fiscal challenges, expansion impact, funding imbalances, and reform options including work requirements and provider tax schemes driving federal costs.

CMS accelerates Medicare price negotiations for drugs with hyaluronidase, impacting biologic drug pricing and pharmaceutical companies like Halozyme Therapeutics and Johnson & Johnson.

House Republicans propose $880 billion in Medicaid cuts as part of major healthcare legislation aiming to fund $4.5 trillion in tax breaks, stirring significant health policy debate.

President Trump announces an executive order aiming to reduce U.S. prescription drug prices by 30-80% through a 'Most Favored Nation' pricing policy affecting healthcare and insurance markets.

Democrats call on GOP leaders to stop Medicaid cuts and focus on Medicare Advantage upcoding to reduce $50 billion in federal overpayments and protect healthcare coverage.

The Trump administration plans to reintroduce a 'most favored nation' drug pricing model for Medicare, aiming to align U.S. drug prices with lower international rates. This strategy faces industry opposition but could complement existing Medicare drug price negotiations to reduce costs.

House Republicans propose Medicaid funding caps that could reduce federal support, impacting state budgets and Medicaid coverage for millions, particularly in expansion states like California.

CMS's GUIDE Model is reshaping Medicare dementia care with home-based solutions, virtual nursing, and new respite care reimbursements to improve patient outcomes and reduce costs.

Updates on U.S. healthcare budget reconciliation delays, Medicaid policy debates, Medicare Advantage lawsuits, HHS budget for FY 2026, and new NIH research initiatives shaping insurance and healthcare regulation.